Last updated: August 12, 2026
CLARINEX-D 12 Hour is a prescription extended-release combination of desloratadine 2.5 mg and pseudoephedrine sulfate 120 mg. Its commercial opportunity was tied to seasonal allergic rhinitis, nasal congestion, and the premium historically available for branded antihistamine-decongestant combinations. That opportunity has largely expired. The product’s core composition patents and regulatory exclusivity are no longer commercial barriers, generic substitution is available or technically feasible, and the branded asset has limited current revenue visibility.
Public companies did not report standalone CLARINEX-D 12 Hour revenue. Financial performance must therefore be inferred from broader Clarinex, allergy, respiratory, and prescription-product disclosures. The product’s trajectory was a conventional mature-product decline: strong launch-period positioning, erosion after loss of exclusivity, pressure from OTC alternatives and combination products, and eventual low strategic priority within the successor portfolios of Merck and Organon.
What is CLARINEX-D 12 Hour and how does it work?
CLARINEX-D 12 Hour combines:
| Component |
Strength |
Function |
| Desloratadine |
2.5 mg |
Long-acting H1 antihistamine |
| Pseudoephedrine sulfate |
120 mg |
Nasal decongestant |
| Dosage form |
Extended-release tablet |
Dosed every 12 hours |
Desloratadine is the active metabolite of loratadine. Pseudoephedrine provides systemic vasoconstriction that reduces nasal congestion. The combination addresses symptoms that an antihistamine alone may not control.
The product was developed for prescription treatment of seasonal allergic rhinitis. Its commercial differentiation was convenience, branded quality perception, and combination efficacy rather than a novel mechanism or difficult manufacturing process. The pseudoephedrine component also imposed retail controls under U.S. federal and state restrictions because of its use in illicit methamphetamine production.
The product was marketed by Schering-Plough and later became part of Merck’s portfolio after Merck’s 2009 acquisition of Schering-Plough. Organon subsequently inherited parts of the former Merck women’s health, established brands, and biosimilars portfolio, but CLARINEX-D 12 Hour has not been a major publicly disclosed Organon growth product.
When did CLARINEX-D 12 Hour lose exclusivity?
CLARINEX-D 12 Hour no longer has meaningful market exclusivity. The relevant commercial protection periods ended years ago, although individual patents may have covered particular formulations, manufacturing processes, or related products at different times.
The principal exclusivity drivers were:
- FDA approval of the combination product.
- Patents covering desloratadine and related pharmaceutical compositions.
- Formulation and extended-release technology.
- Pediatric exclusivity, if awarded to the relevant product or active ingredient.
- Brand recognition and prescriber familiarity.
The product’s market position weakened after generic desloratadine products became established and after physicians could prescribe separate antihistamine and decongestant products. OTC allergy brands such as Claritin, Zyrtec, Allegra, and their generic equivalents also reduced the premium available for a prescription combination.
Estimated commercial lifecycle
| Period |
Commercial condition |
| Mid-2000s |
Prescription launch and brand-led growth |
| Late 2000s |
Expansion within the Clarinex franchise; Schering-Plough-to-Merck portfolio transition |
| Early 2010s |
Generic antihistamine pressure and substitution |
| Mid-2010s |
Mature-product erosion; weaker branded differentiation |
| Late 2010s onward |
Low-growth or residual prescription demand, with limited public revenue disclosure |
FDA approval records identify CLARINEX-D 12 Hour as a combination prescription product. The approval was part of the broader Clarinex franchise rather than a product with a long independent market history comparable with major primary-care drugs (U.S. Food and Drug Administration [FDA], n.d.-a).
What patents protect CLARINEX-D 12 Hour?
The relevant patent estate historically included patents covering desloratadine, related compositions, and the extended-release combination. The strongest historical protection was associated with the active pharmaceutical ingredient and the branded Clarinex franchise, not with a highly complex delivery platform.
Patent categories
| Patent category |
Relevance to CLARINEX-D 12 Hour |
Current commercial effect |
| Desloratadine composition patents |
Protected the active antihistamine |
Expired or commercially exhausted |
| Combination-product patents |
Covered desloratadine with pseudoephedrine |
Limited current blocking value |
| Extended-release formulation patents |
Covered 12-hour release characteristics |
Potentially relevant to generic design-around |
| Manufacturing patents |
Covered production or processing methods |
Usually difficult to enforce against finished-dose competitors |
| Method-of-use patents |
Covered allergic-rhinitis treatment |
Weak protection after underlying composition loss |
The Orange Book must be reviewed by NDA and dosage form because patents listed for Clarinex, CLARINEX-D 12 Hour, and CLARINEX-D 24 Hour are not necessarily interchangeable. FDA’s Orange Book identifies listed patents and regulatory exclusivities associated with approved products, but listing status does not establish ultimate patent validity or infringement (FDA, n.d.-b).
The practical conclusion is that the product’s patent estate is weak as a current commercial barrier. A generic manufacturer can generally pursue an ANDA strategy through patent certification, expiration-based timing, or formulation design-around. Extended-release tablets may create technical development work, but they do not provide the durable protection associated with biologics, complex injectables, or device-linked delivery systems.
What is the Orange Book status of CLARINEX-D 12 Hour?
CLARINEX-D 12 Hour is an FDA-approved prescription product associated with the Clarinex NDA franchise. Orange Book analysis should distinguish:
- The 12-hour extended-release tablet.
- The 24-hour extended-release product.
- Immediate-release desloratadine products.
- Generic desloratadine products without pseudoephedrine.
- Other antihistamine-decongestant combinations.
The Orange Book is the relevant source for current listed patents, therapeutic equivalence codes, and approved product status. A product may remain in FDA historical records even after the branded manufacturer stops active commercial promotion. FDA drug databases also distinguish approval status from current marketing activity (FDA, n.d.-a; FDA, n.d.-b).
There is no strategic reason to treat an old listing as evidence of an active, enforceable market monopoly. The economic question is whether a listed patent remains unexpired and whether a generic can obtain approval with a viable commercial launch. For CLARINEX-D 12 Hour, those conditions have generally favored generic or substitute competition.
How strong is the CLARINEX-D 12 Hour patent estate?
The patent estate is weak to moderate from a historical perspective and weak from a present-day investment perspective.
Strengths
- The combination offered a defined clinical use and recognizable dosage regimen.
- Extended-release formulation work could impose bioequivalence and manufacturing requirements.
- Pseudoephedrine handling and controlled retail distribution add operational complexity.
Weaknesses
- Desloratadine is a small-molecule active ingredient with established generic chemistry.
- The product does not depend on a proprietary device or biologic manufacturing platform.
- Seasonal allergy symptoms have many substitute therapies.
- Separate generic desloratadine and pseudoephedrine products can replicate much of the clinical utility.
- Brand promotion cannot sustain a large premium once generic alternatives are available.
The residual barriers are therefore regulatory and operational rather than patent-based. A prospective entrant must demonstrate extended-release performance, manage pseudoephedrine distribution requirements, and obtain sufficient pharmacy access. Those barriers can delay entry but are unlikely to preserve substantial long-term pricing power.
Which companies challenged or could challenge CLARINEX-D 12 Hour?
The generic competitive field includes companies with established oral solid-dose manufacturing and allergy-product portfolios. Potential or historical competitors include Teva, Mylan, Actavis, Perrigo, Sandoz, and other ANDA sponsors.
The principal competitive paths are:
- A direct generic desloratadine-pseudoephedrine extended-release tablet.
- Separate generic desloratadine plus pseudoephedrine therapy.
- OTC antihistamine-decongestant combinations.
- Intranasal corticosteroids for congestion and inflammation.
- Newer antihistamines that avoid pseudoephedrine exposure.
A Paragraph IV challenge would have been relevant only while a listed patent remained unexpired. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. The commercial value of such a challenge declines sharply when the brand has already lost most of its prescription volume or when multiple therapeutic substitutes are available.
No major, current Paragraph IV litigation involving CLARINEX-D 12 Hour is a central market event. The product’s economic profile is more consistent with ordinary post-exclusivity erosion than with an active patent dispute.
What formulation patents protect the 12-hour product?
The 12-hour dosage form depends on extended release of pseudoephedrine and sustained exposure to desloratadine. Formulation protection could address:
- Matrix or coated-tablet release technology.
- Release-control excipients.
- Layered or multi-phase tablets.
- Dissolution profiles.
- Stability of the combination.
- Manufacturing steps that preserve release characteristics.
Formulation patents are more relevant to generic entry than method-of-use patents because a generic applicant must match the reference product’s release profile and demonstrate bioequivalence. Even so, formulation patents generally have lower durability than active-ingredient patents. A competitor may use a different excipient system or tablet architecture if it achieves the required pharmacokinetic and dissolution profile.
The product has no known manufacturing barrier comparable with sterile injectable products, antibody production, or highly specialized inhalation devices. Its manufacturing risk is principally formulation control, analytical testing, supply of active ingredients, and compliance with pseudoephedrine distribution restrictions.
What is the FDA regulatory status of CLARINEX-D 12 Hour?
CLARINEX-D 12 Hour followed the conventional NDA pathway for a prescription small-molecule combination. The FDA-approved labeling identified seasonal allergic rhinitis as the principal indication and included warnings associated with pseudoephedrine, including cardiovascular and central nervous system effects.
Key regulatory considerations include:
- Contraindications in patients with certain cardiovascular conditions.
- Caution in hypertension, hyperthyroidism, glaucoma, urinary retention, and other conditions.
- Potential interactions with monoamine oxidase inhibitors.
- Restrictions related to pseudoephedrine sales and recordkeeping.
- Need for an ANDA sponsor to establish pharmaceutical equivalence and bioequivalence.
Regulatory risk is low for the established reference product because the safety and efficacy profile is well characterized. Commercial risk is higher because the product is exposed to substitution, reduced prescription utilization, and competition from non-pseudoephedrine therapies.
What was the financial trajectory of CLARINEX-D 12 Hour?
No standalone revenue series for CLARINEX-D 12 Hour is publicly reported. Merck and Schering-Plough disclosed product and franchise information at broader levels, while later Organon reporting emphasizes major current brands and therapeutic areas rather than this individual product.
The financial trajectory can be assessed through market structure:
| Financial driver |
Effect on CLARINEX-D 12 Hour |
| Initial branded prescription demand |
Positive during launch and franchise expansion |
| Generic desloratadine |
Reduced pricing and substitution resistance |
| OTC Claritin and competing allergy brands |
Reduced prescription need |
| Pseudoephedrine restrictions |
Increased purchase friction |
| Seasonal demand |
Created volume concentration and forecasting variability |
| Generic combination products |
Compressed net price |
| Portfolio rationalization |
Reduced promotional investment |
| Lack of clinical differentiation |
Limited ability to regain share |
The product likely generated its highest economic value before broad generic competition and before the market fully shifted toward OTC allergy treatment. After that point, revenue would have declined through lower volume, lower net price, reduced sales-force support, and greater substitution.
The product was never likely to be a major independent earnings driver compared with the broader Claritin franchise. Claritin had substantial commercial scale, while Clarinex and CLARINEX-D were positioned as prescription extensions of the allergy franchise. Corporate disclosures from Merck after the Schering-Plough transaction emphasized portfolio integration and established-product management rather than a renewed growth strategy for this product class (Merck & Co., 2010).
How does CLARINEX-D 12 Hour compare with competing allergy drugs?
| Product or class |
Main advantage |
Main disadvantage |
Competitive effect |
| CLARINEX-D 12 Hour |
Combined antihistamine and decongestant |
Prescription status, pseudoephedrine restrictions |
Limited residual niche |
| Generic desloratadine |
Low price, antihistamine efficacy |
Does not directly replace decongestant effect |
Strong substitution |
| Claritin OTC |
Brand familiarity and access |
Less prescription-channel relevance |
Reduces branded prescription demand |
| Zyrtec/cetirizine |
Strong allergy recognition |
Sedation concerns in some patients |
Direct antihistamine competitor |
| Allegra/fexofenadine |
Low sedation profile |
Does not provide pseudoephedrine unless combined |
Strong OTC alternative |
| Intranasal steroids |
Effective congestion control |
Administration preference and adherence issues |
Reduces need for oral decongestant |
| Other antihistamine-decongestants |
Similar symptom coverage |
Comparable pseudoephedrine restrictions |
Limits pricing power |
The product’s clinical positioning is most vulnerable in patients who can use an intranasal corticosteroid or a lower-cost antihistamine. Its remaining niche is convenience for patients seeking an oral product that treats both allergy symptoms and congestion.
What generic launch risks exist for CLARINEX-D 12 Hour?
Generic entry risk is high because the product is a small-molecule oral tablet with established active ingredients and no biologic comparability problem.
The main launch scenarios are:
Direct generic launch
A generic sponsor markets a therapeutically equivalent extended-release tablet after patent or regulatory barriers expire. This produces the fastest price erosion.
Formulation design-around
A sponsor develops a different extended-release matrix or coating while matching the required pharmacokinetic profile. This reduces the relevance of narrow formulation claims.
Therapeutic substitution
Pharmacies or prescribers substitute separate generic desloratadine and pseudoephedrine, even without a direct combination equivalent. This can capture much of the product’s demand.
OTC displacement
Patients purchase generic Claritin, Zyrtec, Allegra, nasal steroids, or other nonprescription products. This shifts demand outside the branded prescription market.
The most credible branded defense would have been contracting, physician promotion, patient support, or a new formulation. None creates durable protection once the active ingredients and treatment category are commoditized.
What patent litigation and settlement agreements affect CLARINEX-D 12 Hour?
CLARINEX-D 12 Hour does not have a publicly prominent current litigation profile comparable with major blockbuster drugs. Historical litigation risk would have centered on:
- Validity of desloratadine composition claims.
- Infringement of extended-release formulation claims.
- ANDA Paragraph IV certifications.
- Generic launch timing.
- Settlement terms involving licensed entry dates.
No material current settlement agreement is widely identified as a central determinant of the product’s market value. The absence of active litigation does not create renewed exclusivity. It reflects the product’s mature lifecycle and reduced commercial stakes.
What licensing deals affected CLARINEX-D 12 Hour?
The principal ownership transition was corporate rather than a product-specific licensing transaction:
- Schering-Plough developed and commercialized the Clarinex franchise.
- Merck acquired Schering-Plough in 2009.
- Organon later became an independent company with selected products from the former Merck portfolio.
Public disclosures do not identify a major standalone licensing deal that materially changed the economic trajectory of CLARINEX-D 12 Hour. The commercial outcome was driven by portfolio ownership, generic competition, and category substitution.
What geographic markets remain commercially relevant?
The United States was the most important market for the product because of its prescription infrastructure, branded allergy market, and pseudoephedrine demand. International opportunity was constrained by:
- Different regulatory treatment of pseudoephedrine.
- Country-specific approval requirements.
- Local generic competition.
- Availability of alternative antihistamines.
- Varying use of prescription versus OTC allergy products.
A global growth thesis is weak. The product is a mature oral combination without meaningful geographic exclusivity. Any remaining value is likely concentrated in localized generic or residual branded channels rather than broad international expansion.
Key Takeaways
- CLARINEX-D 12 Hour combines desloratadine 2.5 mg with pseudoephedrine 120 mg in a 12-hour extended-release tablet.
- Its commercial protection has expired or lost practical significance.
- The product’s patent estate is less important today than generic formulation capability and FDA approval timing.
- Direct and indirect generic competition is substantial.
- OTC antihistamines, intranasal steroids, and separate desloratadine-pseudoephedrine therapy reduce demand.
- No standalone public revenue series exists for CLARINEX-D 12 Hour.
- The financial trajectory is consistent with post-exclusivity decline, lower pricing, reduced promotion, and portfolio rationalization.
- Current investment value is limited unless linked to a broader generic platform, manufacturing capability, or established prescription distribution network.
- The product does not present a meaningful biosimilar risk because it is a conventional small-molecule tablet.
- No major current patent litigation or settlement appears to support a renewed branded market position.
FAQs
Is CLARINEX-D 12 Hour still sold in the United States?
The product remains identifiable through historical FDA approval and labeling records, but its current branded commercial presence is limited. Market availability depends on manufacturer, wholesaler, pharmacy, and generic status.
Is CLARINEX-D 12 Hour the same as Claritin-D?
Both products combine an antihistamine with pseudoephedrine, but CLARINEX-D contains desloratadine while Claritin-D contains loratadine. They are related but not identical products.
Does CLARINEX-D 12 Hour have biosimilar competition?
No. Biosimilars apply to biologic products. CLARINEX-D 12 Hour is a small-molecule oral combination and faces generic, not biosimilar, competition.
Can a generic manufacturer substitute separate desloratadine and pseudoephedrine for CLARINEX-D 12 Hour?
Separate products can reproduce the two active ingredients, but they are not necessarily pharmaceutically equivalent to the fixed-dose extended-release combination. Substitution depends on prescription instructions, state law, payer policy, and pharmacist authority.
Is pseudoephedrine still a commercial barrier for generic CLARINEX-D 12 Hour?
Pseudoephedrine creates supply-chain, retail-control, and compliance requirements. Those factors raise operating complexity but are unlikely to preserve durable pricing power against an established generic manufacturer.
References
-
Merck & Co., Inc. (2010). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2009. U.S. Securities and Exchange Commission.
-
Organon & Co. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (n.d.-c). CLARINEX-D 12 Hour prescribing information. FDA-approved labeling.
